B Mirror Report: Renata PLC has received marketing authorisation (MA) in the United Kingdom for its Esomeprazole 20 mg and 40 mg gastro-resistant tablets, approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The drug, marketed in Bangladesh under the brand name Maxpro MUPS, is used for managing gastro-oesophageal reflux disease (GERD), treating erosive reflux oesophagitis, preventing rebleeding of peptic ulcers following intravenous therapy, and treating Zollinger–Ellison syndrome.

Maxpro MUPS is manufactured using Multiple Unit Pellet System (MUPS) technology, which embeds multiple enteric-coated pellets within each tablet. This design ensures uniform dispersion in the gastrointestinal tract, consistent intestinal absorption, and reduces the risk of dose dumping. The gastro-resistant formulation prevents premature degradation of the drug, enabling targeted release at the intended site, thereby enhancing efficacy and tolerability.

Renata first introduced MUPS technology in Bangladesh, transforming the local esomeprazole market by setting new standards in formulation efficiency and therapeutic reliability. Maxpro MUPS has become one of the most recognised brands in the gastrointestinal segment, and alongside Maxpro, remains among Renata’s highest-selling products widely prescribed by healthcare professionals.

The UK approval marks a major milestone for Renata, as one of its flagship formulations enters a highly regulated international market. The development reflects the company’s growth from local pharmaceutical innovation to international regulatory recognition, demonstrating its increasing capability to deliver value-added medicines globally.